COMMUNIQUÉS West-GlobeNewswire

Baylor Genetics to Showcase Genetic Testing Innovations for Rare Disease at ACMG 2025 Annual Clinical Genetics Meeting

11/03/2025 - 15:00

HOUSTON, March 11, 2025 (GLOBE NEWSWIRE) -- As Baylor Genetics celebrates a decade of leadership at the forefront of genetic testing, it is set to exhibit its latest scientific studies in genetic testing at the 2025 [...]

Biofrontera Inc. to Report Fourth Quarter and Full Year 2024 Financial Results on March 21, 2025

11/03/2025 - 15:00

WOBURN, Mass., March 11, 2025 (GLOBE NEWSWIRE) -- Biofrontera Inc. (NASDAQ:BFRI), a biopharmaceutical company specializing in the development and commercialization of dermatological products, today announced that it [...]

Smith+Nephew to showcase advanced Orthopaedic Reconstruction technologies for Robotics, Knees, Hips, and Shoulders at AAOS 2025

11/03/2025 - 16:00

Smith+Nephew (LSE:SN, NYSE:SNN), the global medical technology company, today announces it will feature the latest advancements in Orthopaedic Reconstruction at the American Academy of Orthopaedic Surgeons Annual [...]

OSE Immunotherapeutics et le GERCOR annoncent des premiers résultats cliniques positifs de OSE2101 (Tedopi®) dans l’essai clinique de Phase 2 TEDOPaM dans le cancer du pancréas avancé

11/03/2025 - 18:00

OSE Immunotherapeutics et le GERCOR annoncent des premiers résultats cliniques positifs de OSE2101 (Tedopi®) dans l’essai clinique de Phase 2 TEDOPaM dans le cancer du pancréas avancé Critère principal atteint dans l’ [...]

OSE Immunotherapeutics and GERCOR Announce Positive Topline Phase 2 Result for Clinical Trial TEDOPaM Evaluating OSE2101 (Tedopi®) in Advanced Pancreatic Cancer

11/03/2025 - 18:00

OSE Immunotherapeutics and GERCOR Announce Positive Topline Phase 2 Result for Clinical Trial TEDOPaM Evaluating OSE2101 (Tedopi®) in Advanced Pancreatic Cancer Primary endpoint met in randomized Phase 2 trial [...]

EssilorLuxottica: Nombre total de droits de vote et d’actions composant le capital social au 28 février 2025

11/03/2025 - 18:00

Nombre total de droits de vote et d’actions composant le capital social au 28 février 2025 (Conformément à l’article L.233-8 II du Code de Commerce et aux articles 221-1 et 223-16 du Règlement Général de l’AMF) Paris, [...]

EssilorLuxottica: Disclosure of Share Capital and Voting Rights Outstanding as of February 28, 2025

11/03/2025 - 18:00

Disclosure of Share Capital and Voting Rights Outstanding as of February 28, 2025 (Pursuant to Article L.233-8 II of the French Commercial Code and articles 221-1 and 223-16 of the General Regulations of the Autorité [...]

Nymox Announces Dismissal of Delaware Action Against Ascella

11/03/2025 - 18:51

IRVINE, Calif., March 11, 2025 (GLOBE NEWSWIRE) -- Nymox announces that it dismissed the Delaware matter pending against Ascella on March 7, 2025. A number of factors caused the company to reconsider its strategy to [...]

Tilray Medical lance Tilray Craft et introduit des variétés génétiques à forte teneur en THC et en terpènes sur le marché allemand du cannabis thérapeutique

11/03/2025 - 19:12

NEUMÜNSTER, Allemagne, 11 mars 2025 (GLOBE NEWSWIRE) -- Tilray Medical, (« Tilray »), une division de Tilray Brands, Inc. (NASDAQ : TLRY et TSX : TLRY) et un leader mondial du cannabis thérapeutique qui permet aux [...]

Dianthus Therapeutics Highlights Recent Business Achievements and Reports Q4 and FY 2024 Financial Results

11/03/2025 - 21:01

Phase 2 MaGic trial of DNTH103 in generalized Myasthenia Gravis (gMG) ongoing; top-line results on track for 2H’25 Phase 3 CAPTIVATE trial of DNTH103 in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) ongoing; [...]

Voyager Reports Fourth Quarter and Full Year 2024 Financial and Operating Results

11/03/2025 - 21:01

- Tau silencing gene therapy VY1706 robustly reduced tau mRNA levels, with broad distribution, and was well-tolerated in NHP study; IND filing anticipated in 2026 - - Anti-tau antibody VY7523 was well tolerated in [...]

Mural Oncology Announces Fourth Quarter and Year End 2024 Financial Results and Highlights Upcoming Clinical Milestones

11/03/2025 - 21:01

Interim analysis of overall survival in potentially registrational phase 3 ARTISTRY-7 trial in platinum-resistant ovarian cancer expected in late Q1/early Q2 2025 Top-line data readout of potentially registrational [...]

Verrica Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results

11/03/2025 - 21:05

– Company generated quarterly sequential growth in YCANTH ® dispensed applicator units of 12.3% in Q4’24 concurrent with significantly lower operating expenses – – Company reports positive quarterly revenue earlier than [...]

SIGA Reports Financial Results for Three and Twelve Months Ended December 31, 2024

11/03/2025 - 21:05

Increased Product Sales to $133 Million in 2024 Generated Pre-tax Operating Income and Net Income of $70 Million and $59 Million, Respectively, in 2024 Corporate Update Conference Call Today at 4:30 PM ET NEW YORK, [...]

MaxCyte Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Full Year 2025 Guidance

11/03/2025 - 21:05

ROCKVILLE, Md., March 11, 2025 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (NASDAQ: MXCT; LSE: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and [...]

Sanara MedTech to Report Fourth Quarter and Full Year 2024 Financial Results on March 25, 2025

11/03/2025 - 21:05

FORT WORTH, TX, March 11, 2025 (GLOBE NEWSWIRE) -- Sanara MedTech Inc . (“Sanara,” or the “Company”) (Nasdaq: SMTI), a medical technology company focused on developing and commercializing transformative technologies to [...]

Lyell Immunopharma Reports Business Highlights and Financial Results for the Fourth Quarter and Full Year 2024

11/03/2025 - 21:05

Acquired ImmPACT Bio and strengthened clinical pipeline with the addition of IMPT-314, a next-generation dual-targeting CD19/CD20 CAR T-cell product candidate for the treatment of aggressive large B-cell lymphoma (LBCL [...]

MaxCyte Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Full Year 2025 Guidance

11/03/2025 - 21:05

ROCKVILLE, MD, March 11, 2025 — MaxCyte, Inc., (NASDAQ: MXCT; LSE: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization [...]

Zevra Reports Full Year 2024 and Fourth Quarter Financial Results

11/03/2025 - 21:05

FY 2024 net revenue of $23.6 million, driven by net revenue of $12.0 million during fourth quarter of 2024 Entered into asset purchase agreement for sale of PRV for $150 million Company to host conference call and [...]